Cephalon Bolstering Sales Force Ahead Of Multiple Launches Expected In ‘06
Executive Summary
Cephalon is actively recruiting representatives for what could become three separate sales forces to support multiple new product launches in 2006
You may also be interested in...
FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
A broad label for Cephalon's Treanda could increase the sales potential for the chronic lymphocytic leukemia therapy, which can be used across multiple lines of treatment and as monotherapy or in combination regimens
FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
A broad label for Cephalon's Treanda could increase the sales potential for the chronic lymphocytic leukemia therapy, which can be used across multiple lines of treatment and as monotherapy or in combination regimens
Cephalon/CIMA Merger Clears FTC: Generic Actiq To Ensure Price Competition
The Federal Trade Comission has taken the unprecedented step of allowing a brand name pharmaceutical manufacturer to establish a generic alternative for a drug rather than divest it to ensure market competition